Literature DB >> 21153629

Rosiglitazone: a European regulatory perspective.

E Blind1, K Dunder, P A de Graeff, E Abadie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21153629     DOI： 10.1007/s00125-010-1992-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  17 in total

1.  Rosiglitazone--continued uncertainty about safety.

Authors:  Jeffrey M Drazen; Stephen Morrissey; Gregory D Curfman
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

2.  The record on rosiglitazone and the risk of myocardial infarction.

Authors:  Bruce M Psaty; Curt D Furberg
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

3.  Patient-important outcomes in diabetes--time for consensus.

Authors:  Victor M Montori; Gunjan Y Gandhi; Gordon H Guyatt
Journal:  Lancet       Date:  2007-09-29       Impact factor: 79.321

4.  Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.

Authors:  Debra A Wertz; Chun-Lan Chang; Chaitanya A Sarawate; Vincent J Willey; Mark J Cziraky; Rhonda L Bohn
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-08-24

5.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Authors:  David J Graham; Rita Ouellet-Hellstrom; Thomas E MaCurdy; Farzana Ali; Christopher Sholley; Christopher Worrall; Jeffrey A Kelman
Journal:  JAMA       Date:  2010-06-28       Impact factor: 56.272

Review 6.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  Arch Intern Med       Date:  2010-07-26

7.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2008-10-22       Impact factor: 10.122

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

10.  Rosiglitazone RECORD study: glucose control outcomes at 18 months.

Authors:  P D Home; N P Jones; S J Pocock; H Beck-Nielsen; R Gomis; M Hanefeld; M Komajda; P Curtis
Journal:  Diabet Med       Date:  2007-06       Impact factor: 4.359
View more
  15 in total

1.  Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Authors:  Rikje Ruiter; Loes E Visser; Myrthe P P van Herk-Sukel; Petronella H Geelhoed-Duijvestijn; Sandra de Bie; Sabine M J M Straus; Peter G M Mol; Silvana A Romio; Ron M C Herings; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

2.  Identifying plausible adverse drug reactions using knowledge extracted from the literature.

Authors:  Ning Shang; Hua Xu; Thomas C Rindflesch; Trevor Cohen
Journal:  J Biomed Inform       Date:  2014-07-19       Impact factor: 6.317

Review 3.  β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  World J Diabetes       Date:  2015-02-15

4.  PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

Authors:  Siripong Palee; Siriporn Chattipakorn; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  World J Cardiol       Date:  2011-05-26

Review 5.  Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.

Authors:  Boaz Hirshberg; Arie Katz
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

6.  A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials.

Authors:  Kaitlyn M Gayvert; Neel S Madhukar; Olivier Elemento
Journal:  Cell Chem Biol       Date:  2016-09-15       Impact factor: 8.116

Review 7.  Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

Authors:  Feng Zhang; Desong Kong; Yin Lu; Shizhong Zheng
Journal:  Cell Mol Life Sci       Date:  2012-06-15       Impact factor: 9.261

8.  Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.

Authors:  Gavin O'Mahony; Jens Petersen; Margareta Ek; Rebecca Rae; Carina Johansson; Liu Jianming; Nina Prokoph; Fredrik Bergström; Krister Bamberg; Fabrizio Giordanetto; Bader Zarrouki; Daniel Karlsson; Anders Hogner
Journal:  ACS Med Chem Lett       Date:  2022-03-11       Impact factor: 4.632

9.  Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes.

Authors:  Paul Paolini; Daniel Pick; Jennifer Lapira; Giuseppina Sannino; Lorenza Pasqualini; Colleen Ludka; L James Sprague; Xian Zhang; Elesha A Bartolotta; Esteban Vazquez-Hidalgo; David Torres Barba; Carlos Bazan; Gary Hardiman
Journal:  Pharmacogenomics       Date:  2014-04       Impact factor: 2.533

10.  Tenofovir nephrotoxicity: 2011 update.

Authors:  Beatriz Fernandez-Fernandez; Ana Montoya-Ferrer; Ana B Sanz; Maria D Sanchez-Niño; Maria C Izquierdo; Jonay Poveda; Valeria Sainz-Prestel; Natalia Ortiz-Martin; Alejandro Parra-Rodriguez; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  AIDS Res Treat       Date:  2011-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.